血清NSE、Pro-GRP水平在小细胞肺癌患者中疗效预测价值

Predictive value of serum NSE and Pro-GRP levels in patients with small cell lung cancer

目的探讨血清神经元特异性烯醇化酶(NSE)及胃泌素释放肽前体(Pro-GRP)在小细胞肺癌(SCLC)患者中疗效预测价值。方法回顾性研究2016年2月至2018年12月在复旦大学附属中山医院接受化疗的SCLC患者249例。分析治疗前后血清NSE、Pro-GRP值在各治疗反应组间的差异,分析其对近期疗效的预测价值。结果治疗前,缓解组及稳定组NSE均较进展组明显降低(P值均<0.05)。治疗后,缓解组及稳定组NSE均明显低于进展组(P值均<0.05);与稳定组比较,缓解组治疗后NSE更低(P值<0.05)。治疗后,缓解组Pro-GRP值均较进展组及稳定组明显降低(P值均<0.05)。治疗后,NSE值及Pro-GRP在缓解组13.3(11.4,16.9)μg/L和101.8(59.2,350.3)ng/L与未缓解组21.1(15.0,39.0)μg/L和507.0(82.6,2164.0)ng/L间的差异均有统计学意义(P值均<0.001)。结论治疗SCLC患者中NSE可以预示早期疾病进展。治疗后NSE、Pro-GRP越低预示更好的疗效。NSE、Pro-GRP结合对近期疗效有较好的预测价值。

Objective To investigate the predictive value of serum neuron specific enolase(NSE)and gastrin releasing peptide precursor(Pro-GRP)in treatment of patients with small cell lung cancer(SCLC).Methods Retropective reseach was performed in 249 patients with small cell lung cancer who received chemotherapy at Zhongshan Hospital Fudan University between Feb 2016 and Dec 2018.The difference of serum NSE,Pro-GRP values among the treatment response groups and their predictive value for curative effect were analyzed.Results Before treatment,NSE was significantly lower in remission group and stable group than in progression group(both P<0.05).After treatment,NSE was significantly lower in remission and stable groups than progression group(both P<0.05).NSE was lower in remission group compared to disease stable group(P<0.05).After treatment,Pro-GRP was significantly lower in remission group than in progression and disease stable group(both P<0.05).NSE and Pro-GRP showed significant difference between remission 13.3(11.4,16.9)μg/L,101.8(59.2,350.3)ng/L and non-remission patients 21.1(15.0,39.0)μg/L,507.0(82.6,2164.0)ng/L(P<0.001).Conclusions NSE predicts early disease progression in treatment of SCLC patients.The lower NSE and Pro-GRP after treatment predict better outcome.Combination of NSE and Pro-GRP is highly predictive of recent good outcomes.